Eton Pharmaceutical
ETON
60.85
-0.51
-0.83%
Eton Pharmaceutical
US · ETON
#2944 by market cap
Listed 2018
60.85
-0.51
-0.83%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Company notice
4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.SEC · 2026/7/8
-
Company notice
4/A: Eton Pharmaceutical | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Opaleye Management Inc.SEC · 2026/7/18
-
Rating change
H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $80Market Newswire · 2026/11/6
-
Rating change
Eton Pharmaceuticals (ETON) Gets a Buy From H.C. WainwrightTipRanks · 2026/10/1
-
B. Riley Adjusts Price Target on Eton Pharmaceuticals to $81 From $70, Keeps Buy RatingMT Newswires · 2026/11/10
-
Rating change
H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/11/3
-
Company notice
Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Gruber James R.SEC · 2026/1/15
-
Rating change
B. Riley Securities Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $81Market Newswire · 2026/11/10
-
Form 144 | Eton Pharmaceutical(ETON.US) Director Proposes to Sell 5.34 Million in Common StocksMarket Newswire · 2026/11/11
-
Rating change
Eton Pharmaceuticals Price Target Raised to $81.00/Share From $70.00 by B. Riley SecuritiesDow Jones · 2026/11/11
-
Eton Pharmaceuticals Is Maintained at Buy by B. Riley SecuritiesDow Jones · 2026/11/11
-
Rating change
HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price TargetBenzinga · 2026/10/15
-
Rating change
CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $68Market Newswire · 2026/11/3
-
Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $82Market Newswire · 2026/11/6
-
Rating change
CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $68Market Newswire · 2026/10/15
-
Rating change
CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $80Market Newswire · 2026/11/6
-
Company notice
3: Eton Pharmaceutical | 3: Initial statement of beneficial ownership of securities- Matthews Judith M.SEC · 2026/6/2
-
Rating change
Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $76Market Newswire · 2026/8/14
-
Company notice
4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.SEC · 2026/7/17
-
Eton Pharmaceutical(ETON.US) Director Sells US$5.35 Million in Common StockMarket Newswire · 2026/11/11
-
Rating change
CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/7/30
-
Rating change
B. Riley Adjusts Price Target on Eton Pharmaceuticals to $70 From $40, Maintains Buy RatingMT Newswires · 2026/8/14
-
Rating change
H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/8/11
-
Rating change
Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $62Market Newswire · 2026/7/28
-
Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027Benzinga · 2026/10/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Eton Pharmaceutical discussion 0 comments